Clinical Trial Update: EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial from Sun Yat-sen University evaluating EBV lytic reactivation therapy together with a PD-1 antibody for recurrent/metastatic na…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• EBV Lytic Reactivation Therapy
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Cancinoma (NPC) | Phase 2 | Status: NOT_YET_RECRUITING